NeuroSense’s PrimeC shows microRNA improvement in ALS

NeuroSense (NRSN) announced findings from its PARADIGM clinical trial of PrimeC. These results illuminate a new frontier in the treatment of ALS – Amyotrophic Lateral Sclerosis -, a disease long considered untreatable at its core. The trial demonstrating the significant impact of PrimeC on the regulation of microRNAs, which play a key role in ALS progression, providing compelling evidence of the drug’s potential to alter the underlying mechanisms of the disease. The trial revealed that PrimeC regulates specific miRNAs – key genetic markers that control gene expression involved in ALS progression. These miRNAs were unchanged in the placebo group. By restoring balance to these genetic regulators, PrimeC offers a new method of combating this disease. PrimeC enhances microRNA maturation, addressing the underlying mechanisms of ALS, allowing PrimeC to target disrupted genetic pathways in ALS and potentially slow disease progression and improve patient outcomes. PrimeC demonstrated beneficial regulation of key miRNAs, supporting its potential to engage critical genetic targets involved in ALS progression.